Infect Chemother.  2016 Jun;48(2):127-131. 10.3947/ic.2016.48.2.127.

Recurrent Kikuchi's Disease Treated by Hydroxychloroquine

• Hyun M
• So IT
• Kim HA
• Jung H
• Ryu SY

• KMID: 2327980
• DOI: http://doi.org/10.3947/ic.2016.48.2.127

Abstract

Kikuchi-Fujimoto disease (KFD) is a benign, self-limiting disease, with a specific histopathology. It can be diagnosed clinically, and specific symptoms include fever and cervical lymphadenopathy. The histological finding of KFD in cervical lymph nodes includes necrotizing lymphadenitis. KFD needs conservative treatments. If KFD persists for a long period, steroids or nonsteroidal antiinflammatory drugs can be used to control symptoms. Previous studies have reported the treatment of KFD with hydroxychloroquine (HC) in patients unresponsive to steroids. Herein, we report a case of a 25-year-old female patient diagnosed with KFD unresponsive to steroids, and was successfully treated with HC.

Keyword

Kikuchi-Fujimoto disease; Lymphadenitis; Hydroxychloroquine

MeSH Terms

Adult
Female
Fever
Histiocytic Necrotizing Lymphadenitis*
Humans
Hydroxychloroquine*
Lymph Nodes
Lymphadenitis
Lymphatic Diseases
Steroids
Hydroxychloroquine
Steroids

Figure

• 

  Figure 1 Multiple enlarged or borderline sized LNs in both level II, III, IV, Va, and Vb.Perinodal infiltration is noted around the enlarged lymph nodes(arrows).

• 

  Figure 2 The gross specimen consists of a piece of pale tan soft tissue, 1.5 × 0.8 × 0.7 cm.

• 

  Figure 3 The excisional biopsies of cervical lymph nodes, show (A) aggregates of histiocytes (astra), nonphagocytic and phagocytic, with crescentic nuclei (H&E stains, ×100) and (B) similar findings consisting of many histiocytes with crescent-shaped nuclei (arrowheads) in necrotic background (H&E stains, ×400).

Reference

1. Kikuchi M. Lymphadenitis showing focal reticulum cells hyperplasia with nuclear debris and phagocytosis: A clinicopathological study. Acta Hematol Jpn. 1972; 35:379–380.

2. Fujimoto Y, Kojima Y, Yamaguchi K. Cervical subacute necrotizing lymphadenitis. Naika. 1972; 30:920–927.

3. Song JY, Lee J, Park DW, Sohn JW, Suh SI, Kim IS, Kim WJ, Kim MJ, Cheong HJ. Clinical outcome and predictive factors of recurrence among patients with Kikuchi's disease. Int J Infect Dis. 2009; 13:322–326.

4. Bosch X, Guilabert A, Miquel R, Campo E. Enigmatic Kikuchi-Fujimoto disease: a comprehensive review. Am J Clin Pathol. 2004; 122:141–152.

5. Yoo IH, Na H, Bae EY, Han SB, Lee SY, Jeong DC, Kang JH. Recurrent lymphadenopathy in children with Kikuchi-Fujimoto disease. Eur J Pediatr. 2014; 173:1193–1199.

6. Kucukardali Y, Solmazgul E, Kunter E, Oncul O, Yildirim S, Kaplan M. Kikuchi-Fujimoto Disease: analysis of 244 cases. Clin Rheumatol. 2007; 26:50–54.

7. Hutchinson CB, Wang E. Kikuchi-Fujimoto disease. Arch Pathol Lab Med. 2010; 134:289–293.

8. Rezai K, Kuchipudi S, Chundi V, Ariga R, Loew J, Sha BE. Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment. Clin Infect Dis. 2004; 39:e124–e126.

9. Goldblatt F, Andrews J, Russell A, Isenberg D. Association of Kikuchi-Fujimoto's disease with SLE. Rheumatology (Oxford). 2008; 47:553–554.

10. Nayak HK, Mohanty PK, Mallick S, Bagchi A. Diagnostic dilemma: Kikuchi's disease or tuberculosis? BMJ Case Rep. 2013; 2013:pii:bcr2012008026.

11. Ram R, Swarnalatha G, Adiraju KP, Srinivasan VR, Dakshinamurty KV. Kikuchi–Fujimoto disease associated with systemic lupus erythematosus. NDT Plus. 2011; 4:238–240.

12. Ohshima K, Haraoka S, Takahata Y, Takada H, Tsutiya K, Suzuk K, Suzumiya J, Kikuchi M. Interferon-gamma, interleukin-18, monokine induced by interferon-gamma and interferon-gamma-inducible protein-10 in histiocytic necrotizing lymphadenitis. Leuk Lymphoma. 2002; 43:1115–1120.

13. Facchetti F, Vermi W, Mason D, Colonna M. The plasmacytoid monocyte/interferon producing cells. Virchows Arch. 2003; 443:703–717.

14. Uslu E, Gurbuz S, Erden A, Aykas F, Karagoz H, Karahan S, Karaman H, Cetinkaya A, Avci D. Disseminated intravascular coagulopathy caused by Kikuchi-Fujimoto disease resulting in death: first case report in Turkey. Int Med Case Rep J. 2014; 7:19–22.

15. Lin DY, Villegas MS, Tan PL, Wang S, Shek LP. Severe Kikuchi's disease responsive to immune modulation. Singapore Med J. 2010; 51:e18–e21.

16. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013; 43:264–272.

17. Barrera P, Boerbooms AM, van de Putte LB, van der Meer JW. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum. 1996; 25:234–253.

18. van Loosdregt J, Spreafico R, Rossetti M, Prakken BJ, Lotz M, Albani S. Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. J Allergy Clin Immunol. 2013; 131:1443–1446.e1.

19. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000; 95:3460–3466.

20. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012; 14:R155.